Report finds Januvia may become favored therapy

June 18, 2007

The recent safety concerns regarding the use of the thiazolidinediones pioglitazone (Actos, Takeda) and rosiglitazone (Avandia, GlaxoSmithKline) and the risk that they lead to cardiac failure may cause an increased market uptake of other drugs used to treat Type 2 diabetes.

The recent safety concerns regarding the use of the thiazolidinediones pioglitazone (Actos, Takeda) and rosiglitazone (Avandia, GlaxoSmithKline) and the risk that they lead to cardiac failure may cause an increased market uptake of other drugs used to treat Type 2 diabetes. According to a new report from healthcare market research company Decision Resources, physicians will be more likely to prescribe other treatments, including Merck's Januvia (sitagliptin), the first of the DPP-4 inhibitors. The report, entitled Treatment Algorithms in Type 2 Diabetes, also finds that insulin use remains an option that is utilized in only later lines of therapy, after other more convenient options have failed to treat the condition.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.